{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:28:51Z","timestamp":1761845331454,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Langerhans cell histiocytosis (LCH) is a rare disease characterized by the infiltration of one or more organs by Langerhans cell-like dendritic cells. LCH often involves the bone, and its clinical evidence is limited. The purpose of this study is to report on the treatment of LCH at our institution and to add to the evidence for LCH. Materials and Methods: We reviewed six cases of LCH treated in our hospital between November 2005 and February 2016. Patient age at the first visit, sex, site of origin, symptoms, image tools used for diagnosis, biopsy site, complications, treatment, and final clinical outcome were evaluated. The median follow-up period was 41 months. Results: The median patient age at the first visit was 13.5 years. Three male and three female individuals were enrolled. Multiple lesions were observed in five cases, and a solitary lesion was observed in one case. Pain was the chief complaint in five cases. Radiography was the most commonly used imaging tool. Bone scintigraphy or magnetic resonance imaging and positron emission tomography-computed tomography were also used to diagnose systematic LCH. Biopsy of the femur was performed in two cases, and biopsy of the tibia, lumbar vertebrae, rib, and radius was performed in one case each. Regarding comorbidities, one case of hepatitis B and one case of autism were observed. Chemotherapy was initiated in two patients. The other four patients were observed naturally. Continuous disease-free survival was observed in five patients. One patient remained alive but not without disease during the final follow-up examination. Conclusion: LCH should be diagnosed as early as possible to treat it appropriately.<\/jats:p>","DOI":"10.3390\/medicina57040356","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:31:59Z","timestamp":1617795119000},"page":"356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment Outcomes of Langerhans Cell Histiocytosis: A Retrospective Study"],"prefix":"10.3390","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-0063","authenticated-orcid":false,"given":"Kazuhiko","family":"Hashimoto","sequence":"first","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunji","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kindai University Hospital, Osaka-Sayama City, Osaka 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Osaka Women\u2019s and Children\u2019s Hospital, Izumi City, Osaka 594-1101, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihisa","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Osaka Women\u2019s and Children\u2019s Hospital, Izumi City, Osaka 594-1101, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Akagi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Kindai University Hospital, Osaka-Sayama City, Osaka 589-8511, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"ref_1","unstructured":"Fletcher, C.D., and Lazar, A.J. (2020). WHO classification of tumors of soft tissue and bone. Soft Tissue and Bone Tumours, IARC Publications. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2017.05.059","article-title":"Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis","volume":"78","author":"Krooks","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/his.12481","article-title":"Bone marrow involvement of Langerhans cell histiocytosis: Immunohistochemical evaluation of bone marrow for CD1a, langerin, and S100 expression","volume":"65","author":"Kim","year":"2014","journal-title":"Histopathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/00003086-200010000-00027","article-title":"Langerhans\u2019 cell histiocytosis in patients older than 21 years","volume":"379","author":"Islinger","year":"2000","journal-title":"Clin. Orthop. Relat. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12185-020-02892-z","article-title":"Clinical features and outcomes of adult Langerhans cell histiocytosis: A single-center experience","volume":"112","author":"Kobayashi","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/11538540-000000000-00000","article-title":"Multisystem Langerhans cell histiocytosis in children: Current treatment and future directions","volume":"13","author":"Minkov","year":"2011","journal-title":"Pediatr. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5603\/ARM.a2017.0046","article-title":"Pulmonary Langerhans\u2019 cell histiocytosis in adults","volume":"85","author":"Radzikowska","year":"2017","journal-title":"Adv. Respir. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/1097-0142(19951215)76:12<2471::AID-CNCR2820761211>3.0.CO;2-Z","article-title":"Langerhans\u2019 cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases","volume":"76","author":"Kilpatrick","year":"1995","journal-title":"Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2278::AID-CNCR25>3.0.CO;2-U","article-title":"Langerhans cell histiocytosis: Diagnosis, natural history, management, and outcome","volume":"85","author":"Howarth","year":"1999","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MPH.0000000000000054","article-title":"Korea Histiocytosis Working Party. Clinical features and treatment outcomes of Langerhans cell histiocytosis: A nationwide survey from Korea Histiocytosis Working Party","volume":"36","author":"Kim","year":"2014","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/MOP.0b013e3282f45ba4","article-title":"Langerhans cell histiocytosis: Update for the pediatrician","volume":"20","author":"Weitzman","year":"2008","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/BF01383393","article-title":"Radiographic skeletal survey and radionuclide bone scan in Langerhans cell histiocytosis of bone","volume":"26","author":"Clapuyt","year":"1996","journal-title":"Pediatr. Radiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00247-004-1262-0","article-title":"Langerhans\u2019 cell histiocytosis: Pathology, imaging and treatment of skeletal involvement","volume":"35","author":"Azouz","year":"2005","journal-title":"Pediatr. Radiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/pbc.24367","article-title":"Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years","volume":"60","author":"Haupt","year":"2013","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41598-018-36501-1","article-title":"Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis","volume":"9","author":"Kim","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pbc.21782","article-title":"Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis","volume":"52","author":"Phillips","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s00247-003-0943-4","article-title":"Coincidence FDG-PET in the evaluation of Langerhans\u2019 cell histiocytosis: Preliminary findings","volume":"33","author":"Binkovitz","year":"2003","journal-title":"Pediatr. Radiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00247-007-0467-4","article-title":"PET-CT in pediatric Langerhans cell histiocytosis","volume":"37","author":"Kaste","year":"2007","journal-title":"Pediatr. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s13244-013-0271-7","article-title":"Skeletal involvement in Langerhans cell histiocytosis","volume":"4","author":"Khung","year":"2013","journal-title":"Insights Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3389\/fped.2020.00466","article-title":"A \u201cwait-and-see\u201d approach to quiescent single-system Langerhans cell histiocytosis to spare children from chemotherapy","volume":"8","author":"Oh","year":"2020","journal-title":"Front. Pediatr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","article-title":"Histiocyte Society. Therapy prolongation improves outcome in multi-system Langerhans cell histiocytosis","volume":"121","author":"Gadner","year":"2013","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12185-012-1245-0","article-title":"Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group","volume":"97","author":"Morimoto","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2015-03-635151","article-title":"Cladribine and cytarabine in refractory multi-system Langerhans cell histiocytosis: Results of an international phase 2 study","volume":"126","author":"Donadieu","year":"2015","journal-title":"Blood"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/4\/356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:26:31Z","timestamp":1760361991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/4\/356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["medicina57040356"],"URL":"https:\/\/doi.org\/10.3390\/medicina57040356","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2021,4,7]]}}}